CERENOME, INC. SEC Filings

Plus Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved all four proposals presented. The meeting covered director elections, auditor ratification, executive pay and an updated stock incentive plan.

Six directors were elected to terms ending at the 2027 annual meeting, each receiving over 11.8 million votes in favor, with more than 50.8 million broker non-votes recorded. Stockholders ratified CBIZ CPAs, P.C. as independent auditor for 2026 with 60.9 million votes for and 2.3 million against. On an advisory basis, stockholders approved compensation for named executive officers with about 10.4 million votes for and 3.4 million against. They also approved the sixth amendment and restatement of the 2020 Stock Incentive Plan, which received about 8.0 million votes for and 5.6 million against.

Plus Therapeutics, Inc. reported a net loss of $6.9 million for the three months ended March 31, 2026, on grant revenue of $1.0 million, reflecting heavy research and administrative spending as it develops CNS cancer diagnostics and radiopharmaceuticals.

Cash and cash equivalents were $3.0 million with net cash used in operations of $6.2 million, and management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Stockholders’ equity increased to $12.0 million, supported by a January 2026 public offering and a 1‑for‑25 reverse stock split that helped the company regain compliance with Nasdaq’s minimum bid requirement.

Plus Therapeutics reported first quarter 2026 results and updated progress on its REYOBIQ radiotherapeutic and CNSide diagnostics businesses. Grant and diagnostic revenue was $1.0 million, slightly below the prior year, while the company recorded a larger operating loss of $7.1 million as it expanded R&D and commercial activities.

Net loss narrowed to $6.9 million, or $1.05 per share, compared with a $17.4 million loss, or $29.86 per share, a year earlier, largely due to the absence of prior-period noncash derivative and financing charges. Cash, cash equivalents, and investments rose to $15.1 million as of March 31, 2026, helped by a $15 million upsized public equity offering completed in January.

Operationally, the company advanced its central nervous system oncology platform by securing FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, obtaining new reimbursement codes for REYOBIQ delivery and CNSide, adding a second GMP manufacturing site, and expanding payer coverage for CNSide to about 81 million covered lives while scaling commercial infrastructure.

Plus Therapeutics, Inc. reporting persons CVI Investments, Inc. and Heights Capital Management, Inc. disclosed beneficial ownership of 9,009,978 shares, representing 4.9% of the outstanding common stock. The filing states there were 171,550,698 Shares outstanding as of March 18, 2026.

The reported shares consist of shares issuable upon exercise of warrants, and exercise is limited so that beneficial ownership would not exceed 4.99%. Heights Capital Management, Inc. serves as investment manager and may exercise shared voting and dispositive power over the reported shares.

Plus Therapeutics: Highbridge reports beneficial ownership of warrants exercisable into common stock. The Schedule 13G states 13,157,894 shares of Common Stock are attributable to Highbridge Capital Management, LLC, representing 7.1% of the class based on 171,550,698 shares outstanding as of March 18, 2026. The shares are described as issuable upon exercise of warrants; the filing attributes voting and dispositive powers to the reporting person and names Highbridge Tactical Credit Master Fund, L.P. as a fund holding more than 5%.

PLUS THERAPEUTICS, INC. granted Chief Development Officer Eric Joseph Daniels equity-based compensation. He received stock options covering 20,000 shares of Common Stock at an exercise price of $7.30 per share, expiring on April 19, 2036. One fourth of these options vest on April 20, 2027, with the remaining options vesting in substantially equal monthly installments over the following 36 months.

Daniels was also awarded 20,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. One third of the RSUs vest on July 1, 2027, and the remaining RSUs vest ratably over the next eight quarters in substantially equal increments. These awards are compensation grants rather than open-market purchases or sales.

PLUS THERAPEUTICS, INC. executive Eric Joseph Daniels, Chief Development Officer, filed an initial Form 3 reporting his beneficial ownership of company stock. The filing lists one entry for Common Stock and shows 0 shares owned directly following the reported holdings line.

The transaction section contains no purchases, sales, option exercises, or other transfers, indicating there were no reportable transactions in PLUS Therapeutics stock at the time of this initial ownership statement.

Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company has regained compliance with the exchange’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq found that, from April 6 to April 17, 2026, the closing bid price of the company’s common stock was at or above $1.00 per share.

This followed a one-for-twenty-five reverse split of the company’s common stock, which became effective on April 2, 2026. The company issued a press release on April 21, 2026 announcing the compliance confirmation and noting that Nasdaq has advised the matter is now closed.

Plus Therapeutics, Inc. appointed Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026. He will oversee development and approval of the company’s pharmaceutical pipeline.

Under his employment agreement, Dr. Daniels will receive a $460,000 base salary, a 40% target bonus, 20,000 stock options and 20,000 restricted stock units, along with severance and partial equity vesting acceleration if he is terminated without cause or resigns for good reason.